SLS Sellas Life Sciences Group Inc
Company Analysis
Latest News
🔴 Sellas Life Sciences is trading 12.96% down today ahead of high-risk Phase 3 REGAL readout
Sellas Life Sciences is trading at $9.87, down 12.96%, amid investor caution ahead of the high-risk Phase 3 REGAL readout and concerns over delayed results. -...
🔴 Sellas Life Sciences is trading 4.4% down
Sellas Life Sciences is trading 4.4% down at $10.84 on October 16, 2026, with no new company-specific announcement identified to explain the decline. - Recent...
🔴 Sellas Life Sciences is trading 4.04% down today with no clear catalyst identified
Sellas Life Sciences is trading 4.04% down at $11.40 on October 15, 2026, with no new company-specific catalyst reported. - Prior institutional-ownership...
SELLAS Shares Rise on Fund Buying Ahead of AML Trial Readouts
SELLAS Life Sciences shares rose in premarket trading Wednesday amid increased institutional ownership and anticipation of clinical trial results. The company...
🔴 Sellas Life Sciences is trading 4.43% down today after September inflation topped forecasts
Sellas Life Sciences is trading at $11.86, down 4.43%, as investors react to September CPI above forecasts. - Headline inflation was 3.7% year over year,...
🟢 Sellas Life Sciences is trading 5.3% up on October 13, 2026 with no confirmed explanation
Sellas Life Sciences is trading at $12.56, up 5.32%, with no confirmed explanation for the October 13 rise. - Investors are watching Phase 3 REGAL, reported...
🟢 Sellas Life Sciences rises 4.1% — Biotech Sector Rallies on Strong IPO Debuts and M&A Activity
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a significant rally,...
🔴 Sellas Life Sciences is trading 4.11% down with no identified direct catalyst
Sellas Life Sciences is trading 4.11% down at $10.85 on October 8, 2026; no new company announcement directly explains the decline. - Coverage notes a fresh...
🔴 Sellas Life Sciences is trading 4.13% down with no clear company-specific catalyst
Sellas Life Sciences is trading 4.13% down at $11.15, with no clear company-specific announcement identified to explain the decline. - Available search...
🟢 Sellas Life Sciences is trading 5% up today as weak payrolls support risk-on sentiment
Sellas Life Sciences is trading at $11.88, up 4.90%, alongside a broad market advance as weak September payrolls supported a risk-on response. - Payrolls rose...
🔴 Sellas Life Sciences is trading 4.1% down today with no clear company-specific catalyst
Sellas Life Sciences is now trading 4.1% down at $11.80, with no new company-specific announcement identified to explain the October 1 decline. - Recent buyout...
🟢 Sellas Life Sciences is trading 4.3% up today amid broad market strength
Sellas Life Sciences is trading at $12.01, up 4.34%, amid broad market strength. - Broader markets are higher, with the Nasdaq up 0.94%; this may be...
SELLAS Shares Rally 167% YTD, Drawing Valuation Questions After SLS009 Data
SELLAS Life Sciences drew fresh attention after presenting new preclinical data on its CDK9 inhibitor, SLS009, in pancreatic cancer models at the AACR...
🟢 Sellas Life Sciences is trading 4.04% up today
Sellas Life Sciences is trading at $11.98, up 4.04%, rebounding after September 23’s decline; no clear catalyst for today’s gain was identified. - Shares fell...
🔴 Sellas Life Sciences is trading 4.01% down today amid broad U.S. equity weakness
Sellas Life Sciences is trading 4.01% lower at $11.54, primarily amid broad U.S. equity weakness on September 23, 2026. - The Nasdaq fell 1.02%, the S&P 500...
🟢 Sellas Life Sciences rises 4.3% — Biotech Sector Rallies on Major AI Collaboration Deal and Positive Clinical News
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is trading higher, driven by a...
🔴 Sellas Life Sciences is trading 5% down in pre-market amid reported 80th patient-death event, no results
Sellas Life Sciences is trading now at $11.05, down 5.23%, amid continued investor concern surrounding its Phase 3 REGAL trial and the timing of topline...
🔴 Sellas Life Sciences falls 4.4% — Biotech Sector Declines on Key Drug Trial Failure and Shifting Investor Sentiment
With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
🟢 Sellas Life Sciences is trading 4.37% up today — no verified company-specific catalyst
Sellas Life Sciences is trading 4.37% up now at $12.05, rebounding after its 14.42% decline on September 11, 2026; no verified company-specific catalyst...
🔴 Sellas Life Sciences is trading 10% down in pre-market ahead of Tuesday’s Federal Reserve decision
Sellas Life Sciences is trading 10.39% down at $10.35, with the decline appearing aligned with broader risk-off sentiment ahead of the Federal Reserve...